Medical News Summary: Pfizer releases Bextra risks information


About: Pfizer releases Bextra risks information
Date: 11 December 2004
Source: Canada Newswire
Medical News Summary (summary of medical news story as reported by Canada Newswire): Pfizer had recently sent out an information letter detailing the risks involved with Bextra use. Bextra is used to treat osteoarthritis, adult rheumatoid arthritis and menstrual cramping pain. Pfizer states that the drug shouldn’t be used prior to or following surgery if it can be avoided due to risk of cardiovascular events such as heart attacks and strokes, lung blood clots, leg blood clots and infections. Bextra may also have the side effect of serious skin reactions such as toxic epidermal necrolysis, Stevens-Johnson Syndrome and erythema multiforme. Some of these conditions may lead to death. Bextra use should be discontinued if the patient develops a skin rash, mucosal lesions, mouth sores, breathlessness, wheezing, chest tightness or an allergic reaction. Some of these conditions may require urgent medical attention.
Related Disease Topics: Osteoarthritis, Adult rheumatoid arthritis, Menstrual cramping pain, Cardiovascular disease, Heart attack, Stroke, Blood clot in lung, Blood clot in let, Infection, Toxic epidermal necrolysis, Stevens-Johnson Syndrome, Erythema multiforme, Skin rash, Mucosal lesions, Mouth sores, Breathlessness, Wheezing, Chest tightness (see Chest pressure), Allergic reaction (type of Adverse reaction)

Related Medical News Channels: This medical news summary article refers to the following medical channel categories:

Medical Tools & Articles:

Next articles:

Medical Articles:
CureResearch.comTM Copyright © 2010 Health Grades, Inc. All rights reserved.
Home | Contents | Search | Site Map | Feedback | Contact Us | Terms of Use | Privacy Policy | About Us | Advertise